JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma ...Middle East

SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical...

Read More Details
Finally We wish PressBee provided you with enough information of ( JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma )

Also on site :

• 'Hissing door mid-air': AI flight to Hong Kong spooks flyers; crew use napkins to 'fix' issue
• Prabowo hails BRICS entry, reaffirms Indonesia’s non-aligned stance
• Armed rebels take control of Heineken facilities in DR Congo’s war-hit east